Abstract
In the absence of effective antiviral chemotherapy and still in the context of emerging vaccines for severe acute respiratory syndrome-CoV-2 infections, passive immunotherapy remains a key treatment and possible prevention strategy. What might initially be conceived as a simplified donor—recipient process, the intricacies of donor plasma, IV immunoglobulins, and monoclonal antibody modality applications are becoming more apparent. Key targets of such treatment have largely focused on virus neutralization and the specific viral components of the attachment Spike protein and its constituents (e.g., receptor binding domain, N-terminal domain). The cumulative laboratory and clinical experience suggests that beneficial protective and treatment outcomes are possible. Both a dose- and a time-dependency emerge. Lesser understood are the concepts of bioavailability and distribution. Apart from direct antigen binding from protective immunoglobulins, antibody effector functions have potential roles in outcome. In attempting to mimic the natural but variable response to infection or vaccination, a strong functional polyclonal approach attracts the potential benefits of attacking antigen diversity, high antibody avidity, antibody persistence, and protection against escape viral mutation. The availability and ease of administration for any passive immunotherapy product must be considered in the current climate of need. There is never a perfect product, but yet there is considerable room for improving patient outcomes. Given the variability of human genetics, immunity, and disease, and given the nuances of the virus and its potential for change, passive immunotherapy can be developed that will be effective for some but not all patients. An understanding of such patient variability and limitations is just as important as the understanding of the direct interactions between immunotherapy and virus.
Article PDF
Avoid common mistakes on your manuscript.
References
Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010;38;e66–e73.
Cimolai N. Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences. Int J Antimicrob Agents 2021;57;106257.
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211;80–90.
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021;384;619–29.
Cimolai N. Complicating infections associated with common endemic human respiratory coronaviruses. Health Secur 2021; 19;195–208.
Cimolai N. A minimalist strategy towards temporarily defining protection for COVID-19. SN Compr Clin Med 2020;2;2059–66.
Cimolai N. Applying immune instincts and maternal intelligence from comparative microbiology to COVID-19. SN Compr Clin Med 2020;2;2670–83.
Callow KA. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J Hyg (Lond) 1985;95;173–89.
Callow KA, Parry HF, Sergeant M, Tyrrell DAJ. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect 1990;105;435–46.
Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004;78;3572–7.
Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, et al. Therapy with a severe acute respiratory syndrome–associated coronavirus–neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 2006;193;685–92.
Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, et al. An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19. bioRxiv 2020;2020.11.17.385500 [Preprint].
Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10;676–8.
Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24;44–6.
Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 2015;25;1237–49.
Qiu H, Sun S, Xiao H, Feng J, Guo Y, Tai W, et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East Respiratory Syndrome (MERS)-coronavirus infection. Antiviral Res 2016;132;141–8.
Sivapalasingam S, Saviolakis GA, Kulcsar K, Nakamura A, Conrad T, Hassanein M, et al. Human monoclonal antibody cocktail for the treatment or prophylaxis of Middle East Respiratory Syndrome coronavirus. J Infect Dis 2021;jiab036 [Epub ahead of print].
Abbas AT, El-Kafrawy SA, Sohrab SS, Tabll AA, Hassan AM, Iwata-Yoshikawa N, et al. Anti-S1 MERS-COV IgY specific antibodies decreases lung inflammation and viral antigen positive cells in the human transgenic mouse model. Vaccines (Basel) 2020;8;634.
Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, et al. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antiviral Res 2017;137;125–30.
Kim YS, Aigerim A, Park U, Kim Y, Park H, Rhee JY, et al. Sustained responses of neutralizing antibodies against MERS-CoV in recovered patients and their therapeutic applicability. Clin Infect Dis 2020;ciaa1345 [Epub ahead of print].
de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res 2018;156;64–71.
van Doremalen N, Falzarano D, Ying T, de Wit E, Bushmaker T, Feldmann F, et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res 2017;143;30–7.
Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity 2021;54;340.e6–54.e6.
Laing ED, Sterling SL, Richard SA, Epsi NJ, Coggins S, Samuels EC, et al. Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses. medRxiv 2021; 2021.02.10.21251518 [Preprint].
Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat Commun 2021;12;1152.
Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell 2021;184;1858.e10–64.e10.
Morgenlander WR, Henson SN, Monaco DR, Chen A, Littlefield K, Bloch EM, et al. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. J Clin Invest 2021;131;e146927.
Sakharkar M, Rappazzo CG, Wieland-Alter WF, Hsieh CL, Wrapp D, Esterman ES, et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci Immunol 2021; 6;eabg6916.
Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H, et al. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCov HKU1). Int J Infect Dis 2021;105;304–6.
Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival. medRxiv 2021 [Epub ahead of print].
Cohen CA, Li AP, Hachim A, Hui DS, Kwan MY, Tsang OT, et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. medRxiv 2021;2021.02.02.21250988 [Preprint].
Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. Structural characterization of SARS-CoV-2: where we are, and where we need to be. Front Mol Biosci 2020;7;605236.
Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, et al. Relationship between anti-Spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv 2020;2020.06.08.138990 [Preprint].
Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, et al. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. medRxiv 2020;2020.09.16.20196154 [Preprint].
Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 2020;130;6141–50.
Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun 2020;11;6044.
Secchi M, Bazzigaluppi E, Brigatti C, Marzinotto I, Tresoldi C, Rovere-Querini P, et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J Clin Invest 2020;130;6366–78.
Voss WN, Hou YJ, Johnson NV, Kim JE, Delidakis G, Horton AP, et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma. bioRxiv 2020;2020.12.20.423708 [Preprint].
Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. mBio 2021; 12;e02940-20.
Heffron AS, McIlwain SJ, Baker DA, Amjadi MF, Khullar S, Sethi AK, et al. The landscape of antibody binding to SARS-CoV-2. bioRxiv 2020;2020.10.10.334292 [Preprint].
Martínez-Fleta P, Alfranca A, González-Álvaro I, Casasnovas JM, Fernández-Soto D, Esteso G, et al. SARS-CoV-2 cysteine-like protease antibodies can be detected in serum and saliva of COVID-19–seropositive individuals. J Immunol 2020;205;3130–40.
de Assis RR, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero JM, et al. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. Nat Commun 2021;12;6.
Freedenberg AT, Pan CH, Diehl WE, Romeiser JL, Hwang GR, Leiton CV, et al. Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial. Transfusion 2021 [Epub ahead of print].
Smits VAJ, Hernández-Carralero E, Paz-Cabrera MC, Cabrera E, Hernández-Reyes Y, Hernández-Fernaud JR, et al. The nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochem Biophys Res Commun 2021;543;45–9.
Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020;370;1339–43.
Martin S, Heslan C, Jégou G, Eriksson LA, Le Gallo M, Thibault V, et al. SARS-CoV2 envelop proteins reshape the serological responses of COVID-19 patients. bioRxiv 2021 [Preprint].
Nielsen SCA, Yang F, Jackson KJL, Hoh RA, Röltgen K, Jean GH, et al. Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. Cell Host Microbe 2020;28;516–525.e5.
Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med 2020;26; 1428–34.
Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020;584;437–42.
Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 2020;183;1024.e21–42.e21.
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371;eabf4063.
Li L, Tong X, Chen H, He R, Lv Q, Yang R, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion 2020;60;1765–72.
Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ, et al. Longitudinal dynamics of the neutralizing antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Clin Infect Dis 2020;ciaa1143 [Epub ahead of print].
Beaudoin-Bussières G, Laumaea A, Anand SP, Prévost J, Gasser R, Goyette G, et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio 2020;11; e02590-20.
Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, et al. Neutralizing antibody responses in COVID-19 convalescent sera. J Infect Dis 2021;223;47–55.
De Donno A, Lobreglio G, Panico A, Grassi T, Bagordo F, Bozzetti MP, et al. IgM and IgG profiles reveal peculiar features of humoral immunity response to SARS-CoV-2 infection. Int J Environ Res Public Health 2021;18;1318.
Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, et al. Persistence of SARS-CoV-2 specific B and T-cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med (N Y) 2021;2;281.e4–95.e4.
Kutsuna S, Asai Y, Matsunaga A, Kinoshita N, Terada M, Miyazato Y, et al. Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. J Infect Chemother 2021;27;808–13.
Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol 2020;5;eabe5511.
Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and kinetics of anti–severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. Clin Infect Dis 2021;72;301–8.
Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, et al. Viral and antibody kinetics of COVID-19 patients with different disease severities in acute and convalescent phases: a 6-month follow-up study. Virol Sin 2020;35;820–9.
Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv 2020;2020.07.18.20155374 [Preprint].
Tan Y, Liu F, Xu X, Ling Y, Huang W, Zhu Z, et al. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front Med 2020;14;746–51.
Graham NR, Whitaker AN, Strother CA, Miles AK, Grier D, McElvany BD, et al. Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity. Clin Transl Immunology 2020;9;e1189.
Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 2021;184;169e17–183.e17.
Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. bioRxiv 2021;2021.01.25.428097 [Preprint].
Fischer B, Lindenkamp C, Lichtenberg C, Birschmann IE, Knabbe C, Hendig D. Evidence of long-lasting humoral and cellular immunity against SARS-CoV-2 even in elderly COVID-19 convalescents showing a mild to moderate disease progression. medRxiv 2021 [Preprint].
Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol 2020;11;610300.
Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med 2021;13;eabf1555.
Ladage D, Harzer O, Engel P, Winkler H, Braun RJ. Persisting adaptive immunity to SARS-CoV-2 in Lower Austria. medRxiv 2021 [Preprint].
Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol 2020;147;545.e9–57.e9.
Chen W, Zhang J, Qin X, Wang W, Xu M, Wang LF, et al. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. Biomed Pharmacother 2020;130; 110629.
Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol 2021;18;318–27.
Demaret J, Lefèvre G, Vuotto F, Trauet J, Duhamel A, Labreuche J, et al. Severe SARS-CoV-2 patients develop a higher specific T-cell response. Clin Transl Immunology 2020;9;e1217.
Anichini G, Gandolfo C, Terrosi C, Fabrizi S, Miceli GB, Gori Savellini G, et al. Antibody response to SARS-CoV-2 in infected patients with different clinical outcome. J Med Virol 2021;93;2548–52.
Kowitdamrong E, Puthanakit T, Jantarabenjakul W, Prompetchara E, Suchartlikitwong P, Putcharoen O, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS One 2020;15;e0240502.
Petersen LR, Sami S, Vuong N, Pathela P, Weiss D, Morgenthau BM, et al. Lack of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a large cohort of previously infected persons. Clin Infect Dis 2020;ciaa1685.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591;639–44.
Madariaga MLL, Guthmiller JJ, Schrantz S, Jansen MO, Christensen C, Kumar M, et al. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med 2020;289;559–73.
Jungbauer C, Weseslindtner L, Weidner L, Gänsdorfer S, Farcet MR, Gschalder-Reichhart E, et al. Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations. Transfusion 2021;61;12–16.
Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol 2021;18;936–44.
Mehew J, Johnson R, Roberts D, Harvala H. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. Euro Surveill 2020;25;2001754.
Terpos E, Politou M, Sergentanis TN, Mentis A, Rosati M, Stellas D, et al. Anti-SARS-CoV-2 antibody responses in convalescent plasma donors are increased in hospitalized patients; subanalyses of a phase 2 clinical study. Microorganisms 2020;8;1885.
Ikegami S, Benirschke R, Flanagan T, Tanna N, Klein T, Elue R, et al. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors. Transfusion 2020;60;2962–8.
Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Vande Weygaerde Y, et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol 2021;136;104765.
Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, et al. Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals. medRxiv 2021;2021.02.01.21250493 [Preprint].
Bavaro DF, Laghetti P, Milano E, Brindicci G, Volpe A, Lagioia A, et al. Anti-spike S1 receptor-binding domain antibodies against SARS-CoV-2 persist several months after infection regardless of disease severity. J Med Virol 2021;93;3158–64.
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol 2020;3;780.
Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med 2021;27;454–62.
Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, et al. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosens Bioelectron 2021;178;113008.
Koblischke M, Traugott MT, Medits I, Spitzer FS, Zoufaly A, Weseslindtner L, et al. Dynamics of CD4 T cell and antibody responses in COVID-19 patients with different disease severity. Front Med (Lausanne) 2020;7;592629.
Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al. IgG seroconversion and pathophysiology in severe acute respiratory syndrome coronavirus 2 infection. Emerg Infect Dis 2021;27;85–91.
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 2021; 22;74–85.
Bacher P, Rosati E, Esser D, Rios Martini G, Saggau C, Schiminsky E, et al. Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity 2020;53;1258.e5–71.e5.
Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep 2020;10;20048.
Sakhi H, Dahmane D, Attias P, Kofman T, Bouvier M, Lapidus N, et al. Kinetics of anti–SARS-CoV-2 IgG antibodies in hemodialysis patients six months after infection. J Am Soc Nephrol 2021;ASN.2020111618 [Epub ahead of print].
Hempel L, Molnar J, Robert S, Veloso J, Trepotec Z, Englisch S, et al. Rare SARS-CoV-2 antibody development in cancer patients. Semin Oncol 2021;S0093-7754(20)30124-X [Epub ahead of print].
Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020;183;996.e19–1012.e19.
Zohar T, Loos C, Fischinger S, Atyeo C, Wang C, Slein MD, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 2020;183;1508.e12–19.e12.
Anand SP, Prévost J, Richard J, Perreault J, Tremblay T, Drouin M, et al. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. Transfusion 2021 [Epub ahead of print].
Deisenhammer F, Borena W, Bauer A, Kimpel J, Rudzki D, Schanda K, et al. 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort. Wien Kin Wochenschr 2020;1–8 [Epub ahead of print].
Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann FM, et al. Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2–specific IgG. Emerg Infect Dis 2021;27;122–9.
Girardin RC, Dupuis AP, Payne AF, Sullivan TJ, Strauss D, Parker MM, et al. Temporal analysis of serial donations reveals decrease in neutralizing capacity and justifies revised qualifying criteria for coronavirus disease 2019 convalescent plasma. J Infect Dis 2021;223;743–51.
Harvala H, Mehew J, Robb ML, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill 2020;25;2001260.
Wendel S, Kutner JM, Machado R, Fontão-Wendel R, Bub C, Fachini R, et al. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: preliminary lessons from a voluntary convalescent donor program. Transfusion 2020;60;2938–51.
Schlickeiser S, Schwarz T, Steiner S, Wittke K, Al Besher N, Meyer O, et al. Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses. Front Immunol 2021;11;628971.
Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, et al. S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio 2020;11;e01991-20.
Lee E, Sandgren K, Duette G, Stylianou VV, Khanna R, Eden JS, et al. Identification of SARS-CoV-2 nucleocapsid and spike T-cell epitopes for assessing T-cell immunity. J Virol 2020;95;e02002-20.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, et al. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood 2020;136;2905–17.
Orologas-Stavrou N, Politou M, Rousakis P, Kostopoulos IV, Ntanasis-Stathopoulos I, Jahaj E, et al. Peripheral blood immune profiling of convalescent plasma donors reveals alterations in specific immune subpopulations even at 2 months post SARS-CoV-2 infection. Viruses 2020;13;26.
Peluso MJ, Deitchman AN, Torres L, Iyer NS, Nixon CC, Munter SE, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses across a clinically diverse cohort of individuals recovering from COVID-19. medRxiv 2021; 2021.02.26.21252308.
McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590;630–4.
Brocato RL, Principe LM, Kim RK, Zeng X, Williams JA, Liu Y, et al. Disruption of adaptive immunity enhances disease in SARS-CoV-2 infected Syrian hamsters. J Virol 2020;94;e01683-20.
Bieberich F, Vazquez-Lombardi R, Yermanos A, Ehling RA, Mason DM, Wagner B, et al. A single-cell atlas of lymphocyte adaptive immune repertoires and transcriptomes reveals age-related differences in convalescent COVID-19 patients. bioRxiv 2021 [Preprint].
Neeland MR, Bannister S, Clifford V, Dohle K, Mulholland K, Sutton P, et al. Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. Nat Commun 2021;12;1084.
Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, Gros L. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010;84;10169–81.
Focosi D, Maggi F, Mazzetti P, Pistello M. Viral infection neutralization tests: a focus on severe acute respiratory syndrome coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol 2020;31;e2170.
Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol 2020;20;727–38.
Schmidt F, Weisblum Y, Muecksch F, Hoffmann HH, Michailidis E, Lorenzi JCC, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020;217;e20201181.
Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol 2020;58; e02107-20.
Lv H, Wu NC, Tsang OTY, Yuan M, Perera RAPM, Leung WS, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep 2020;31;107725.
Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med 2021;218;e20201993.
Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, et al. Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome coronavirus 2. J Infect Dis 2021;223;957–70.
Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med 2021;e210366 [Epub ahead of print].
Shields AM, Faustini SE, Kristunas CA, Cook AM, Backhouse C, Dunbar L, et al. Longitudinal protection following natural SARS-CoV-2 infection and early vaccine responses: insights from a cohort of community based dental health care professionals. medRxiv 2021 [Preprint].
Bradfute SB, Hurwitz I, Yingling AV, Ye C, Cheng Q, Noonan TP, et al. Severe acute respiratory syndrome coronavirus 2 neutralizing antibody titers in convalescent plasma and recipients in New Mexico: an open treatment study in patients with coronavirus disease 2019. J Infect Dis 2020;222;1620–8.
Yoon HA, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH, et al. Treatment of severe COVID-19 with convalescent plasma in the Bronx, NYC. medRxiv 2020;2020.12.02.20242909 [Preprint].
Maor Y, Cohen D, Paran N, Israely T, Ezra V, Axelrod O, et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 2020;26;100525.
Salazar E, Kuchipudi SV, Christensen PA, Eagar T, Yi X, Zhao P, et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest 2020;130;6728–38.
Walker GJ, Naing Z, Ospina Stella A, Yeang M, Caguicla J, Ramachandran V, et al. SARS coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays. Viruses 2021;13;247.
Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep 2021;34;108699.
Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of neutralizing antibody titers in the months after Severe Acute Respiratory Syndrome Coronavirus 2 infection. J Infect Dis 2021;223;197–205.
Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med 2020 [Epub ahead of print].
Bryan A, Fink SL, Gattuso MA, Pepper G, Chaudhary A, Wener MH, et al. SARS-CoV-2 viral load on admission is associated with 30-day mortality. Open Forum Infect Dis 2020;7;ofaa535.
Benner SE, Patel EU, Laeyendecker O, Pekosz A, Littlefield K, Eby Y, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis 2020;222;1974–84.
Barnes CO, Jette CA, Abernathy ME, Dam KMA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020;588;682–7.
Li Y, Lai DY, Lei Q, Xu ZW, Wang F, Hou H, et al. Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients. Cell Mol Immunol 2021;18;621–31.
Mishra N, Huang X, Joshi S, Guo C, Ng J, Thakkar R, et al. Immunoreactive peptide maps of SARS-CoV-2. Commun Biol 2021;4;225.
Polvere I, Voccola S, Cardinale G, Fumi M, Aquila F, Parrella A, et al. A peptide-based assay discriminates individual antibody response to SARS-CoV-2. Genes Dis 2021 [Epub ahead of print].
Hayashi T, Yaegashi N, Konishi I. Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity. medRxiv 2021 [Epub ahead of print].
Grabowski F, Kochańczyk M, Lipniacki T. L18F substrain of SARS-CoV-2 VOC-202012/01 is rapidly spreading in England. medRxiv 2021 [Epub ahead of print].
Abdelnabi R, Boudewijns R, Foo CSY, Seldeslachts L, Sanchez-Felipe L, Zhang X, et al. Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters. bioRxiv 2021 [Epub ahead of print].
Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, et al. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. bioRxiv 2021;2021.02.03.429355 [Preprint].
Widera M, Wilhelm A, Hoehl S, Pallas C, Kohmer N, Wolf T, et al. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv 2021 [Preprint].
Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Bohehm L, Raviv Y, et al. SARS-CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera. medRxiv 2021 [Preprint].
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 2021;184;1171.e20–87.e20.
Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv 2021;2021.02.20.432046 [Preprint].
Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv 2021;2021.02.14.21251704 [Preprint].
Tada T, Dcosta BM, Zhou H, Vaill A, Kazmierski W, Landau NR. Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv 2021;2021.02.18.431897 [Preprint].
Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv 2020; 2020.12.28.424451 [Preprint].
Rathnasinghe R, Jangra S, Cupic A, Martínez-Romero C, Mulder LCF, Kehrer T, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv 2021;2021.01.19.21249592 [Preprint].
Ko SH, Mokhtari EB, Mudvari P, Stein S, Stringham CD, Wagner D, et al. High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. bioRxiv 2021;2021.02.21.432184 [Preprint].
Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv 2020;2020.11.06.372037 [Preprint].
Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, et al. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant Spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv 2021;2021.02.05.430003 [Preprint].
Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn A, et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: escape from therapeutic antibodies and antibodies induced by infection and vaccination. bioRxiv 2021 [Preprint].
Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. bioRxiv 2021 [Preprint].
Kemp SA, Collier DA, Datir R, Ferreira I, Gayed S, Jahun A, et al. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv 2020;2020.12.05.20241927 [Preprint].
Diamond M, Chen R, Xie X, Case J, Zhang X, VanBlargan L, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Sq 2021;rs.3.rs-228079 [Preprint].
Li W, Chen C, Drelich A, Martinez DR, Gralinski LE, Sun Z, et al. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2020;117;29832–8.
Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete mapping of mutations to the SARS-CoV-2 Spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 2021;29;44.e9–57.e9.
Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 2020;9;e61312.
Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, et al. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv 2021;2021.02.25.432969 [Epub ahead of print].
Cerutti G, Rapp M, Guo Y, Bahna F, Bimela J, Reddem ER, et al. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. bioRxiv 2021;2021.02.21.432168 [Epub ahead of print].
Bandopadhyay P, D’Rozario R, Lahiri A, Sarif J, Ray Y, Paul SR, et al. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19. J Infect Dis 2021;jiab010 [Epub ahead of print].
Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 2020;584;353–63.
Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 2005;102;797–801.
Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 2020;5;1185–91.
Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun 2021;12;264.
Walker LM, Burton DR. Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray. Nat Rev Immunol 2018;18;297–308.
Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, et al. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight 2021;6;e143129.
Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature 2020;584;450–6.
Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 2020;584;443–9.
Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-CoV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 2020;370;1110–15.
Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A 2020;117;16587–95.
Case JB, Rothlauf PW, Chen RE, Kafai NM, Fox JM, Smith BK, et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 2020;28;465.e4–74.e4.
Zheng J, Wong LYR, Li K, Verma AK, Ortiz ME, Wohlford-Lenane C, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 2021;589;603–7.
Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 2020;182;73.e16–84.e16.
Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, et al. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nat Commun 2021;12;944.
Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Zost SJ, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. bioRxiv 2020;2020.12.28.424554 [Preprint].
Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 2020;369;956–63.
Gu C, Cao X, Wang Z, Hu X, Yao Y, Zhou Y, et al. A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques. bioRxiv 2021 [Preprint].
De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Lorenzi JCC, et al. Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease. bioRxiv 2021; 2021.01.22.427567 [Preprint].
Le Grand R, Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, et al. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Res Sq 2021;rs.3.rs-235272 [Preprint].
Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LYCoV555 in outpatients with covid-19. N Engl J Med 2021;384;229–37.
Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 2021;325;632–44.
Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. J Infect Dis 2020;222;1960–4.
Díez JM, Romero C, Vergara-Alert J, Belló-Perez M, Rodon J, Honrubia JM, et al. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins. Immunotherapy 2020;12;1247–55.
Díez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy 2020;12;571–6.
Farcet MR, Karbiener M, Schwaiger J, Ilk R, Kreil TR. Rapidly increasing SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic. bioRxiv 2021 [Preprint].
Huang C, Fei L, Li W, Xu W, Xie X, Li Q, et al. Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: a retrospective cohort study based on propensity score matching. Int J Infect Dis 2021;105;525–31.
Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. Int Immunopharmacol 2021;90;107205.
Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 2020;20;786.
Mohtadi N, Ghaysouri A, Shirazi S, Ansari S, Shafiee E, Bastani E, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology 2020;548;1–5.
Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 2020;81:318–56.
Farrokhpour M, Rezaie N, Moradi N, Ghaffari Rad F, Izadi S, Azimi M, et al. Infliximab and intravenous gammaglobulin in hospitalized severe COVID-19 patients in intensive care unit. Arch Iran Med 2021;24;139–43.
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383;334–46.
Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest 2020;130;5942–50.
Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 2021;325;855–64.
Budhai A, Wu AA, Hall L, Strauss D, Paradiso S, Alberigo J, et al. How did we rapidly implement a convalescent plasma program? Transfusion 2020;60;1348–55.
Flieder T, Vollmer T, Müller B, Dreier J, Fischer B, Knabbe C, et al. Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. PLoS One 2021;16;e0247665.
Carter JA, Freedenberg AT, Romeiser JL, Talbot LR, Browne NJ, Cosgrove ME, et al. Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors. Transfusion 2021 [Epub ahead of print].
Bloch EM, Crowe EP, Tobian AAR. Coronavirus disease 2019 convalescent plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 neutralizing titer. J Infect Dis 2021;223;740–2.
Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol 2020;58;e02005-20.
Annen K, Morrison TE, DomBourian MG, McCarthy MK, Huey L, Merkel PA, et al. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. Transfusion 2021;61;1148–59.
Gomaa MR, Kandeil A, Mostafa A, Roshdy WH, Kayed AE, Shehata M, et al. Prevalence of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egyptian convalescent plasma donors. Front Microbiol 2020;11;596851.
Andersson MI, Arancibia-Carcamo CV, Auckland K, Baillie JK, Barnes E, Beneke T, et al. SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Res 2020;5;181.
Nomoto H, Kutsuna S, Okuma K, Kuramitsu M, Tezuka K, Ikebe E, et al. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity. J Infect Chemother 2021;27;653–5.
Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020;130;4791–7.
Hacibekiroğlu T, Kalpakçı Y, Genç AC, Hacibekiroğlu İ, Sunu C, Saricaoğlu A, et al. Efficacy of convalescent plasma according to blood groups in COVID-19 patients. Turk J Med Sci 2021;51;45–8.
Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020;136;755–9.
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med 2021;384;610–18.
Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020;158;e9–e13.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323;1582–9.
Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol 2020;92;1890–901.
Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020;35;e149.
Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin 2020;72;159–64.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020;117;9490–6.
Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis 2020;222;38–43.
Liu M, Chen Z, Dai MY, Yang JH, Chen XB, Chen D, et al. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with covid-19. Transfusion 2020; 60;2210–16.
Naeem S, Gohh R, Bayliss G, Cosgrove C, Farmakiotis D, Merhi B, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl Infect Dis 2020;23;e13451.
Wang M, Yang X, Yang F, Zhu X, Sun Z, Bao P, et al. Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report. Medicine (Baltimore) 2020;99;e21596.
Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A, et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther 2020;5;219.
Hu X, Hu C, Jiang D, Zuo Q, Li Y, Wang Y, et al. Effectiveness of convalescent plasma therapy for COVID-19 patients in Hunan, China. Dose Response 2020;18;1559325820979921.
Ji F, Liu W, Hao DA, Cheng J, Tong XC, Hao JG, et al. Use of convalescent plasma therapy in eight individuals with mild COVID-19. New Microbes New Infect 2021;39;100814.
Fung M, Nambiar A, Pandey S, Aldrich JM, Teraoka J, Freise C, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis 2020;e13477 [Epub ahead of print].
Jin H, Reed JC, Liu STH, Ho HE, Lopes JP, Ramsey NB, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract 2020;8;3594.e3–6.e3.
Diorio C, Anderson EM, McNerney KO, Goodwin EC, Chase JC, Bolton MJ, et al. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer 2020;67;e28693.
Schwartz SP, Thompson P, Smith M, Lercher DM, Rimland CA, Bartelt L, et al. Convalescent plasma therapy in four critically ill pediatric patients with coronavirus disease 2019: a case series. Crit Care Explor 2020;2;e0237.
Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transfus Apher Sci 2020;59;102867.
Rahman F, Liu STH, Taimur S, Jacobs S, Sullivan T, Dunn D, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: experience at large transplant center in New York City. Clin Transplant 2020;34;e14089.
Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, et al. Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients. Cancer Med 2020;9;8571–8.
Huang S, Shen C, Xia C, Huang X, Fu Y, Tian L. A retrospective study on the effects of convalescent plasma therapy in 24 patients diagnosed with COVID-19 pneumonia in February and March 2020 at 2 centers in Wuhan, China. Med Sci Monit 2020;26; e928755.
Chen S, Lu C, Li P, Wang L, Wang H, Yang Q, et al. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020;32;1293–8 [Article in Chinese].
Pal P, Ibrahim M, Niu A, Zwezdaryk KJ, Tatje E, Robinson WR, et al. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: a report of 17 patients. Transfus Med 2020 [Epub ahead of print].
Xiao K, Lin Y, Fan Z, Wen Y, Huang H, Wang M, et al. Effect of transfusion convalescent recovery plasma in patients with coronavirus disease 2019. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2020;45;565–70 [Article in English, Chinese].
Gemici A, Bilgen H, Erdoğan C, Kansu A, Olmuşçelik O, Beköz HS, et al. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma. Turk J Med Sci 2020;50;1781–5.
Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 2020;136;2290–5.
Cantore I, Valente P. Convalescent plasma from COVID-19 patients enhances intensive care unit survival rate: a preliminary report. Transfus Apher Sci 2020;59;102848.
González SE, Regairaz L, Ferrando NS, González Martinez VV, Salazar MR, Estenssoro E. [Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires]. Medicina (B Aires) 2020;80;417–24 [Article in Spanish].
Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc 2020;95;1888–97.
Nguyen FT, van den Akker T, Lally K, Lam H, Lenskaya V, Liu STH, et al. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. Transfusion 2021;61;78–93.
Wu Y, Hong K, Ruan L, Yang X, Zhang J, Xu J, et al. Patients with prolonged positivity of SARS-CoV-2 RNA benefit from convalescent plasma therapy: a retrospective study. Virol Sin 2020;35;768–75.
Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020;2020.08.12.20169359 [Preprint].
Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 2020;105;2834–40.
Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol 2020;190;1680–90.
Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, et al. Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized Phase II clinical trial. medRxiv 2020 [Preprint].
Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther 2020;9;913–26.
Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest. Transl Med Commun 2020;5;17.
González SE, Regairaz L, Salazar MR, Ferrando NS, González Martinez VV, Carrera Ramos PM, et al. Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia. medRxiv 2021 [Preprint].
Janaka SK, Hartman W, Mou H, Farzan M, Stramer SL, Goodhue E, et al. Donor anti-Spike immunity is related to recipient recovery and can predict the efficacy of convalescent plasma units. medRxiv 2021 [Preprint].
Abolghasemi H, Eshghi P, Cheraghali AM, Fooladi AAI, Bolouki Moghaddam F, Imanizadeh S, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci 2020;59;102875.
Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol 2020;190;2290–303.
Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, et al. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci 2021;60;102955.
Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med 2020;26;1708–13.
Rogers R, Shehadeh F, Mylona EK, Rich J, Neill M, Touzard-Romo F, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis 2020; ciaa1548 [Epub ahead of print].
Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein IgG. Am J Pathol 2021;191;90–107.
Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood 2020;136;759–62.
Omrani AS, Zaqout A, Baiou A, Daghfal J, Elkum N, Alattar RA, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report. J Med Virol 2021;93;1678–86.
Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis 2021;103;439–46.
Dai W, Wu J, Li T, Shen J, Pang R, Luo T, et al. Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China. J Med Virol 2021;93;2321–31.
Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, Tomasiewicz K, Pancewicz S, Rorat M, et al. Convalescent plasma transfusion for the treatment of COVID-19—experience from Poland: a multicenter study. J Clin Med 2021;10;28.
Sturek JM, Thomas TA, Gorham JD, Sheppard CA, Raymond AE, Petros De Guex K, et al. Convalescent plasma for preventing critical illness in COVID-19: a phase 2 trial and immune profile. medRxiv 2021;2021.02.16.21251849 [Preprint].
Sostin OV, Rajapakse P, Cruser B, Wakefield D, Cruser D, Petrini J. A matched cohort study of convalescent plasma therapy for COVID-19. J Clin Apher 2021 [Epub ahead of print].
Mesina FZ, Mangahas CG, Gatchalian EM, Ariola-Ramos MS, Torres RP. Use of convalescent plasma therapy among hospitalized coronavirus disease 2019 (COVID-19) patients: a single-center experience. medRxiv 2021 [Epub ahead of print].
Klapholz M, Pentakota SR, Zertuche JP, McKenna M, Roque W, Forsberg M, et al. Matched cohort study of convalescent COVID-19 plasma treatment in severely or life threateningly ill COVID-19 patients. Open Forum Infect Dis 2021;8;ofab001.
AlShehry N, Zaidi SZA, AlAskar A, Al Odayani A, Alotaibi JM, AlSagheir A, et al. Safety and efficacy of convalescent plasma for severe COVID-19: interim report of a multicenter phase II study from Saudi Arabia. Saudi J Med Med Sci 2021;9;16–23.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324;460–70.
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicenter randomized controlled trial (PLACID Trial). BMJ 2020;371;m3939.
Avendaño-Solà C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, Malo de Molina R, Torres F, et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv 2020 [Preprint].
Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 2020;28;357–66.
Gharbharan A, Jordans CCE, Guertsvankessel C, den Hollander JG, Karim F, Mollema FPN, et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv 2020 [Preprint].
Skrip L, Derra K, Kaboré M, Noori N, Gansané A, Valéa I, et al. Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis. Int J Infect Dis 2020;101;194–200.
Jaiswal V, Nasa P, Raouf M, Gupta M, Dewedar H, Mohammad H, et al. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19—an exploratory study. Int J Infect Dis 2021;102;332–4.
Selzman CH, Tonna JE, Pierce J, Vargas C, Skidmore C, Lewis G, et al. A pilot trial of human amniotic fluid for the treatment of COVID-19. BMC Res Notes 2021;14;32.
Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 2017;6;576–88.
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49;633–59.
Melamed IR, Borte M, Trawnicek L, Kobayashi AL, Kobayashi RH, Knutsen A, et al. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: analysis of a phase III, multicenter, prospective, open-label study. Eur J Pharm Sci 2018;118;80–6.
Koleba T, Ensom MHH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 2006; 26;813–27.
Hahn RG, Lyons G. The half-life of infusion fluids: an educational review. Eur J Anaesthesiol 2016;33;475–82.
Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, et al. Increased vascular permeability: a major cause of hypoalbuminemia in disease and injury. Lancet 1985;325;781–4.
Pathak EB. Convalescent plasma is ineffective for COVID-19. BMJ 2020;371;m4072.
Martinez DR, Schaefer A, Leist SR, Gully K, Feng JY, Bunyan E, et al. Early therapy with remdesivir and antibody combinations improves COVID-19 disease in mice. bioRxiv 2021;2021.01.27.428478 [Preprint].
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Cimolai, N. Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clin Hematol Int 3, 47–68 (2021). https://doi.org/10.2991/chi.k.210328.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.k.210328.001